Shift Pharmaceuticals partners with CMT Research Foundation to further research CMT1A treatment

CMT Research Foundation funds Shift to explore novel series of drugs created to control the expression of PMP22 gene Overland Park: In late January, the CMT Research Foundation (CMTRF) announced a partnership with Shift Pharmaceuticals … Continue reading Shift Pharmaceuticals partners with CMT Research Foundation to further research CMT1A treatment